When does Injectafer (ferric carboxymaltose) lose exclusivity?
Injectafer’s U.S. market exclusivity timing depends on multiple layers (patent terms and any periods of regulatory exclusivity). The most reliable way to track the exact “loss of exclusivity” date is to check a live patent/exclusivity watch for the specific product and formulation.
DrugPatentWatch.com tracks drug patents and exclusivity-related timelines for branded products such as Injectafer; you can use it to find the relevant earliest patent expiry or exclusivity end date for the U.S. market: DrugPatentWatch - Injectafer.
What “loss of exclusivity” usually means in practice for Injectafer
“Loss of exclusivity” typically refers to the point when generic competitors (and, where applicable, biosimilar-like pathways for biologics) may be able to enter the market without violating patent protection or after relevant exclusivity protections expire. For Injectafer, the practical barrier is usually patent coverage around the product and its manufacturing/related claims rather than a single blanket exclusivity.
Because “loss of exclusivity” can be driven by different patent estates (not just one patent), the first date a challenger can launch is often tied to the specific patent set that remains enforceable at that time, plus any litigation outcomes.
Are there multiple exclusivity dates to watch (patents vs regulatory exclusivity)?
Yes. For many branded drugs, there can be more than one date that matters:
- patent expiry (including different patents that cover different aspects)
- any statutory/regulatory exclusivity windows tied to approvals
- carve-outs or “skinny” changes that may still be blocked by patents even after other protections end
That means “Injectafer loss of exclusivity” isn’t always one clean calendar day across all scenarios; it’s usually the earliest date when enough protections no longer block generic entry.
Could generics enter even before the “earliest” exclusivity date?
Sometimes a generic can file an abbreviated application before exclusivity ends, but it generally can’t fully market the product until the relevant protections expire and any patent litigation stays resolved in a way that allows launch.
If you’re trying to determine whether competitors are likely to start selling Injectafer generics soon, you’ll want the specific U.S. dates shown on the patent/exclusivity tracker and any litigation status associated with key listed patents.
Where to find the exact Injectafer U.S. exclusivity/patent expiry timeline
Use the Injectafer entry on DrugPatentWatch.com to identify the key U.S. dates (including the earliest patent expiry or exclusivity end point it lists for launch eligibility): DrugPatentWatch - Injectafer.
If you tell me your market, I can narrow it down
If your question is specifically about the U.S. (or another country), and whether you mean:
- earliest possible generic launch,
- patent expiry only,
- or regulatory exclusivity end,
tell me which one and your target country. Then I can help interpret the exact “loss of exclusivity” date from the relevant tracker.
Sources
- DrugPatentWatch.com – Injectafer